Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone.
Four patients receiving platinum-containing chemotherapy were treated with domperidone (20 mg) by slow intravenous injection followed by a continuous infusion for 24 h at a dose of 10 mg 24 h-1 kg-1. Cardiac monitoring and plasma potassium and domperidone concentration measurements were performed. Severe cardiac arrhythmias occurred in two patients. A control group of 14 patients treated with similar chemotherapy, without domperidone, also underwent cardiac and plasma potassium monitoring. No significant arrhythmias were seen. The electrophysiologic effects of domperidone are discussed. It is concluded that treatment with intravenous domperidone is associated with the occurrence of cardiac arrhythmias.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002945:Cisplatin / Q000627:therapeutic use; D004294:Domperidone / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000188:drug therapy; D011188:Potassium / Q000097:blood
D000970:Antineoplastic Agents; D004294:Domperidone; D002945:Cisplatin; D011188:Potassium